IP Library Granted Patent US 10,065,919
Granted Patent B2
US 10,065,919 · App. 15/368,280 · Granted Sep 4, 2018

Ionizable cationic lipids

Inventors: Frank DeRosa (Chelmsford, MA); Braydon Charles Guild (Concord, MA); Michael Heartlein (Boxborough, MA)
Assignee: Translate Bio, Inc.
C07C211/21A61K9/1271A61K9/1272A61K9/5015A61K38/1816A61K38/47C12N15/85C12Y302/01023
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,065,919
App. No.
15/368,280
Granted
Sep 4, 2018
Kind
B2
Abstract

Disclosed herein are novel compounds, pharmaceutical compositions comprising such compounds and related methods of their use. The compounds described herein are useful, e.g., as liposomal delivery vehicles to facilitate the delivery of encapsulated polynucleotides to target cells and subsequent transfection of said target cells, and in certain embodiments are characterized as having one or more properties that afford such compounds advantages relative to other similarly classified lipids.

Claims (38)

1. A lipid nanoparticle comprising a lipid compound having the structure:

wherein

R 1 and R 2 are each independently selected from the group consisting of hydrogen, an optionally substituted, variably saturated or unsaturated C 1 -C 20 alkyl and an optionally substituted, variably saturated or unsaturated C 6 -C 20 acyl;

L 1 and L 2 are each independently optionally substituted polyunsaturated C 6 -C 20 alkenyl;

m and o are each independently zero, one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, or twenty; and

n is one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, or twenty.

2. The lipid nanoparticle of claim 1 , comprising one or more polynucleotides.

3. The lipid nanoparticle of claim 2 , comprising encapsulated DNA or RNA.

4. The lipid nanoparticle of claim 3 , wherein said RNA is mRNA.

5. The lipid nanoparticle of claim 4 , wherein said mRNA encodes a protein or an enzyme selected from the group consisting of human growth hormone, erythropoietin, α1-antitrypsin, acid alpha glucosidase, arylsulfatase A, carboxypeptidase N, α-galactosidase A, alpha-L-iduronidase, iduronate-2-sulfatase, iduronate sulfatase, N-acetylglucosamine-1-phosphate transferase, N-acetylglucosaminidase, alpha-glucosaminide acetyltransferase, N-acetylglucosamine 6-sulfatase, N-acetylgalactosamine-4-sulfatase, beta-glucosidase, galactose-6-sulfate sulfatase, beta-galactosidase, beta-glucuronidase, glucocerebrosidase, heparan sulfamidase, heparin-N-sulfatase, lysosomal acid lipase, hyaluronidase, galactocerebrosidase, ornithine transcarbamylase (OTC), carbamoyl-phosphate synthetase 1 (CPS1), argininosuccinate synthetase (ASS1), argininosuccinate lyase (ASL), arginase 1 (ARG1), cystic fibrosis transmembrane conductance regulator (CFTR), survival motor neuron (SMN), Factor VIII, Factor IX and low density lipoprotein receptors (LDLR).

6. The lipid nanoparticle of claim 1 , further comprising one or more lipids selected from the group consisting of a cationic lipid, a neutral lipid, a PEG-modified lipid, a non-cationic lipid and a helper lipid.

7. The lipid nanoparticle of claim 1 , wherein L 1 and L 2 are each an optionally substituted polyunsaturated C 18 alkenyl.

8. The lipid nanoparticle of claim 2 , wherein said lipid compound is:

9. A lipid nanoparticle comprising a lipid compound having the structure:

wherein

R 1 and R 2 are each independently selected from the group consisting of an optionally substituted, variably saturated or unsaturated C 6 -C 20 alkyl and an optionally substituted, variably saturated or unsaturated C 6 -C 20 acyl;

L 1 and L 2 are each independently optionally substituted polyunsaturated C 6 -C 20 alkenyl; and

m, n and o are each independently selected from the group consisting of zero, one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, or twenty.

10. The lipid nanoparticle of claim 9 , comprising one or more polynucleotides.

11. The lipid nanoparticle of claim 10 , comprising encapsulated DNA or RNA.

12. The lipid nanoparticle of claim 11 , wherein said RNA is mRNA.

13. The lipid nanoparticle of claim 12 , wherein said mRNA encodes a protein or an enzyme selected from the group consisting of human growth hormone, erythropoietin, α1-antitrypsin, acid alpha glucosidase, arylsulfatase A, carboxypeptidase N, α-galactosidase A, alpha-L-iduronidase, iduronate-2-sulfatase, iduronate sulfatase, N-acetylglucosamine-1-phosphate transferase, N-acetylglucosaminidase, alpha-glucosaminide acetyltransferase, N-acetylglucosamine 6-sulfatase, N-acetylgalactosamine -4-sulfatase, beta-glucosidase, galactose-6-sulfate sulfatase, beta-galactosidase, beta-glucuronidase, glucocerebrosidase, heparan sulfamidase, heparin-N-sulfatase, lysosomal acid lipase, hyaluronidase, galactocerebrosidase, ornithine transcarbamylase (OTC), carbamoyl-phosphate synthetase 1 (CPS1), argininosuccinate synthetase (ASS1), argininosuccinate lyase (ASL), arginase 1 (ARG1), cystic fibrosis transmembrane conductance regulator (CFTR), survival motor neuron (SMN), Factor VIII, Factor IX and low density lipoprotein receptors (LDLR).

14. The lipid nanoparticle of claim 9 , further comprising one or more lipids selected from the group consisting of a cationic lipid, a neutral lipid, a PEG-modified lipid, a non-cationic lipid and a helper lipid.

15. The lipid nanoparticle of claim 9 , wherein L 1 and L 2 are each an optionally substituted polyunsaturated C 18 alkenyl.

16. A lipid nanoparticle comprising:

a lipid compound having the structure:

 wherein

R 1 and R 2 are each independently selected from the group consisting of an optionally substituted, variably saturated or unsaturated C 1 -C 20 alkyl and an optionally substituted, variably saturated or unsaturated C 6 -C 20 acyl;

L 1 and L 2 are each independently unsubstituted polyunsaturated C 18 alkenyl; and

x is selected from the group consisting of a C 5 -C 20 alkyl and a variably unsaturated C 1 -C 20 alkenyl; and

one or more polynucleotides.

17. The lipid nanoparticle of claim 16 , comprising encapsulated DNA or RNA.

18. The lipid nanoparticle of claim 17 , wherein said RNA is mRNA.

19. The lipid nanoparticle of claim 18 , wherein said mRNA encodes a protein or an enzyme selected from the group consisting of human growth hormone, erythropoietin, α1-antitrypsin, acid alpha glucosidase, arylsulfatase A, carboxypeptidase N, α-galactosidase A, alpha-L-iduronidase, iduronate-2-sulfatase, iduronate sulfatase, N-acetylglucosamine-1-phosphate transferase, N-acetylglucosaminidase, alpha-glucosaminide acetyltransferase, N-acetylglucosamine 6-sulfatase, N-acetylgalactosamine-4-sulfatase, beta-glucosidase, galactose-6-sulfate sulfatase, beta-galactosidase, beta-glucuronidase, glucocerebrosidase, heparan sulfamidase, heparin-N-sulfatase, lysosomal acid lipase, hyaluronidase, galactocerebrosidase, ornithine transcarbamylase (OTC), carbamoyl-phosphate synthetase 1 (CPS1), argininosuccinate synthetase (ASS1), argininosuccinate lyase (ASL), arginase 1 (ARG1), cystic fibrosis transmembrane conductance regulator (CFTR), survival motor neuron (SMN), Factor VIII, Factor IX and low density lipoprotein receptors (LDLR).

20. The lipid nanoparticle of claim 16 , further comprising one or more lipids selected from the group consisting of a cationic lipid, a neutral lipid, a PEG-modified lipid, a non-cationic lipid and a helper lipid.

21. The lipid nanoparticle of claim 16 , wherein x is a C 6 - 10 alkenyl or a C 6 - 10 alkyl.

22. The lipid nanoparticle of claim 16 , wherein said lipid compound is:

23. The lipid nanoparticle of claim 16 , wherein said lipid compoud is:

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 21, 2017
From: DEROSA, FRANK; GUILD, BRAYDON CHARLES; HEARTLEIN, MICHAEL
To: SHIRE HUMAN GENETIC THERAPIES, INC.
Reel/Frame 044460/0950 →
CHANGE OF NAME Recorded Jul 20, 2017
From: RANA THERAPEUTICS, INC.
To: TRANSLATE BIO, INC.
Reel/Frame 043267/0165 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 6, 2017
From: SHIRE HUMAN GENETIC THERAPIES, INC.
To: RANA THERAPEUTICS, INC.
Reel/Frame 042177/0032 →
Continuity (3)
Continuation 14389023
Provisional Application 61617468 · Mar 29, 2012
Related Publication 20170240501A1 · Aug 24, 2017